Nonallergic angioedema: Role of bradykinin

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 8, 2007, Pages 842-856

  Bas, M ^b   Adams, V ^c   Suvorava, T ^b   Niehues, T ^b   Hoffmann, T K ^b   Kojda, G ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Allergy; Angioedema; Angiotenin II receptor type 1 antagonists; Angiotensin converting enzyme inhibitors; Bradykinin; C1 INH; Ecallantide; Icatibant

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANDROGEN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; ATORVASTATIN; BRADYKININ; BRADYKININ RECEPTOR; CANDESARTAN; CAPTOPRIL; CLEMASTINE; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; LEVOTHYROXINE; METHYLPREDNISOLONE; OMAPATRILAT; PHENPROCOUMON; SOTALOL; STANOZOLOL; TAMSULOSIN; TRANEXAMIC ACID; TRIAMTERENE;

ABDOMINAL PAIN; ANAMNESIS; ANGIONEUROTIC EDEMA; BONE DEFECT; CHOLESTASIS; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE CLASSIFICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENETIC DISORDER; GROWTH DISORDER; HEART FAILURE; HEART INFARCTION; HIRSUTISM; HUMAN; HYPERTENSION; INDUCED HYPOTENSION; LARYNGOSCOPY; LIVER ADENOMA; LIVER CARCINOMA; LIVER DISEASE; LIVER INJURY; LIVER NECROSIS; MUSCLE NECROSIS; MYALGIA; NAUSEA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHYSICAL EXAMINATION; PREMATURE EPIPHYSIAL CLOSURE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; THROMBOSIS; TRACHEOTOMY; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

ANGIONEUROTIC EDEMA; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; RECOMBINANT PROTEINS;

EID: 34447128795     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01427.x     Document Type: Review

References (131)

1. Bas M, Hoffmann TK, Kojda G. Evaluation and management of angioedema of the head and neck. Curr Opin Otolaryngol Head Neck Surg 2006 14 : 170 175.
2. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001 24 : 599 606.
3. Zuberbier T. Urticaria. Allergy 2003 58 : 1224 1234.
4. Morwood K, Gillis D, Smith W, Kette F. Aspirin-sensitive asthma. Intern Med J 2005 35 : 240 246.
5. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005 53 : 373 388.
6. Alsenz J, Bork K, Loos M. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987 316 : 1360 1366.
7. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992 71 : 206 215.
8. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000 356 : 608 609.
9. Agostoni A, ygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004 114 : S51 S131.
10. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996 98 : 283 287.
11. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006 332 : 1177 1181.
12. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007 98 : 57 63.
13. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 349 : 1893 190.
14. Abelous J, Bardier E. Les substance hypotensive de lúrine humaine normale. CR Soc Biol 1909 66 : 511 512.
15. Sharma JN. Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors? Gen Pharmacol 1990 21 : 451 457.
16. Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001 382 : 5 14.
17. Britos J, Nolly H. Kinin-forming enzyme of rat cardiac tissue. Subcellular distribution and biochemical properties. Hypertension 1981 3 : II-5.
18. Sharma JN, Kesavarao U. Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacology 1996 33 : 341 343.
19. Sharma JN, Uma K, Yusof AP. Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 1998 63 : 229 235.
20. Nustad K, Vaaje K, Pierce JV. Synthesis of kallikreins by rat kidney slices. Br J Pharmacol 1975 53 : 229 234.
21. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970 214 : 374 376.
22. Yang HY, Erdos EG, Levin Y. Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther 1971 177 : 291 300.
23. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985 6 : 161 164.
24. Roberts RA. Bradykinin receptors: characterization, distribution and mechanisms of signal transduction. Prog Growth Factor Res 1989 1 : 237 252.
25. Regoli D, Rhaleb NE, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990 15 (Suppl. 6 S30 S38.
26. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980 32 : 1 46.
27. Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992 184 : 260 268.
28. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P et al. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci U S A 1991 88 : 7724 7728.
29. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA et al. Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994 269 : 21583 21586.
30. Ma JX, Wang DZ, Ward DC, Chen L, Dessai T, Chao J et al. Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. Genomics 1994 23 : 362 369.
31. Chai KX, Ni A, Wang D, Ward DC, Chao J, Chao L. Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. Genomics 1996 31 : 51 57.
32. Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 1981 71 : 105 115.
33. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992 44 : 1 80.
34. Busse R, Fleming I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol Sci 2003 24 : 24 29.
35. Venema VJ, Ju H, Sun J, Eaton DC, Marrero MB, Venema RC. Bradykinin stimulates the tyrosine phosphorylation and bradykinin B2 receptor association of phospholipase C gamma 1 in vascular endothelial cells. Biochem Biophys Res Commun 1998 246 : 70 75.
36. Fleming I, Busse R. Tyrosine phosphorylation and bradykinin-induced signaling in endothelial cells. Am J Cardiol 1997 80 : 102A 109A.
37. Adams DJ, Barakeh J, Laskey R, Van BC. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J 1989 3 : 2389 2400.
38. Martin TW, Wysolmerski RB. Ca2+-dependent and Ca2+-independent pathways for release of arachidonic acid from phosphatidylinositol in endothelial cells. J Biol Chem 1987 262 : 13086 13092.
39. Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. Biochem J 2000 351 : 257 264.
40. Bae SW, Kim HS, Cha YN, Park YS, Jo SA, Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem Biophys Res Commun 2003 306 : 981 987.
41. Madeddu P, Emanueli C, Gaspa L, Salis B, Milia AF, Chao L et al. Role of the bradykinin B2 receptor in the maturation of blood pressure phenotype: lesson from transgenic and knockout mice. Immunopharmacology 1999 44 : 9 13.
42. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002 109 : 1057 1063.
43. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995 92 : 3424 3430.
44. Hall JM. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 1992 56 : 131 190.
45. Ellis EF, Heizer ML, Hambrecht GS, Holt SA, Stewart JM, Vavrek RJ. Inhibition of bradykinin- and kallikrein-induced cerebral arteriolar dilation by a specific bradykinin antagonist. Stroke 1987 18 : 792 795.
46. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004 3 : 845 852.
47. Duchene J, Schanstra JP, Pecher C, Pizard A, Susini C, Esteve JP et al. A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem 2002 277 : 40375 40383.
48. Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980 18 : 787 795.
49. Cocks TM, Angus JA, Campbell JH, Campbell GR. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol 1985 123 : 310 320.
50. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987 327 : 524 526.
51. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986 320 : 454 456.
52. Mombouli JV, Nakashima M, Hamra M, Vanhoutte PM. Endothelium-dependent relaxation and hyperpolarization evoked by bradykinin in canine coronary arteries: enhancement by exercise-training. Br J Pharmacol 1996 117 : 413 418.
53. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985 66 : 835 839.
54. Giannella E, Mochmann HC, Levi R. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res 1997 81 : 415 422.
55. Zhu P, Zaugg CE, Simper D, Hornstein P, Allegrini PR, Buser PT. Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide, and prostacyclin. Cardiovasc Res 1995 29 : 658 663.
56. Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999 34 : 639 650.
57. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 1998 31 : 39 44.
58. Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M et al. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 2003 41 : 1151 1155.
59. Fuller RW, Dixon CM, Cuss FM, Barnes PJ. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis 1987 135 : 176 180.
60. Tsukagoshi H, Sun J, Kwon O, Barnes PJ, Chung KF. Role of neutral endopeptidase in bronchial hyperresponsiveness to bradykinin induced by IL-1 beta. J Appl Physiol 1995 78 : 921 927.
61. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000 36 : 127 131.
62. Hulsmann AR, Raatgeep HR, Saxena PR, Kerrebijn KF, de Jongste JC. Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta 2 and thromboxane prostanoid receptors. Am J Respir Crit Care Med 1994 150 : 1012 1018.
63. Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 1996 224 : 625 630.
64. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 1997 96 : 3570 3578.
65. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998 50 : 357 386.
66. Feletou M, Bonnardel E, Canet E. Bradykinin and changes in microvascular permeability in the hamster cheek pouch: role of nitric oxide. Br J Pharmacol 1996 118 : 1371 1376.
67. Campos MM, Souza GE, Calixto JB. In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol 1999 127 : 1851 1859.
68. Dray A. Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol 1997 75 : 704 712.
69. Lerner UH. Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants. Oral Surg Oral Med Oral Pathol 1994 78 : 481 493.
70. Cruwys SC, Garrett NE, Perkins MN, Blake DR, Kidd BL. The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol 1994 113 : 940 944.
71. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001 429 : 161 176.
72. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995 95 : 1710 1716.
73. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr., Walther T et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 2000 97 : 8140 8145.
74. Ni A, Yin H, Agata J, Yang Z, Chao L, Chao J. Overexpression of kinin B1 receptors induces hypertensive response to des-Arg9-bradykinin and susceptibility to inflammation. J Biol Chem 2003 278 : 219 225.
75. Yang C, Hsu WH. Glucose-dependency of bradykinin-induced insulin secretion from the perfused rat pancreas. Regul Pept 1997 71 : 23 28.
76. Damas J, Bourdon V, Lefebvre PJ. Insulin sensitivity, clearance and release in kininogen-deficient rats. Exp Physiol 1999 84 : 549 557.
77. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001 38 : 1355 1360.
78. Rett K, Wicklmayr M, Dietze GJ. Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol 1990 15 (Suppl. 6 S57 S59.
79. Kishi K, Muromoto N, Nakaya Y, Miyata I, Hagi A, Hayashi H et al. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 1998 47 : 550 558.
80. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 342 : 145 153.
81. Goring HD, Bork K, Spath PJ, Bauer R, Ziemer A, Hintner H et al. Hereditary angioedema in the German-speaking region. Hautarzt 1998 49 : 114 122.
82. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005 27 : 286 298.
83. Joseph K, Kaplan AP. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv Immunol 2005 86 : 159 208.
84. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol 2004 114 : 629 637.
85. Blanch A, Roche O, Urrutia I, Gamboa P, Fontan G, Lopez-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006 118 : 1330 1335.
86. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003 82 : 274 281.
87. Markovic SN, Inwards DJ, Frigas EA, Phyliky RP. Acquired C1 esterase inhibitor deficiency. Ann Intern Med 2000 132 : 144 150.
88. Danielsson A, Nilsson TK, Uddenfeldt P. Alterations in C1 inhibitor and clotting factor concentrations in primary biliary cirrhosis and other chronic liver diseases. Scand J Gastro- enterol 1990 25 : 149 154.
89. Cohen H, Hunt JB, Dixit M, Kanwar S, Thomas HC. Decreased contact factor mediated fibrinolysis in cirrhosis. Br J Haematol 1993 85 : 542 545.
90. Gaur S, Cooley J, Aish L, Weinstein R. Lymphoma-associated paraneoplastic angioedema with normal C1-inhibitor activity: does danazol work? Am J Hematol 2004 77 : 296 298.
91. Monnier N, Ponard D, Duponchel C, Csopaki F, Bouillet L, Tosi M et al. Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma. Mol Immunol 2006 43 : 2161 2168.
92. Lefebvre J, Murphey LJ, Hartert TV, Jiao SR, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002 39 : 460 464.
93. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006 129 : 169S 173S.
94. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998 339 : 1285 1292.
95. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998 351 : 1693 1697.
96. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004 17 : 103 111.
97. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005 111 : 315 320.
98. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996 334 : 1649 1654.
99. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998 31 : 349 355.
100. Hellebrand MC, Kojda G, Hoffmann TK, Bas M. Angioedema due to ACE inhibitors and AT(1) receptor antagonists. Hautarzt 2005 57 : 808 810.
101. Jessup M, Brozena S. Heart failure. N Engl J Med 2003 348 : 2007 2018.
102. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005 366 : 2026 2033.
103. Kaplan NM, Opie LH. Controversies in hypertension. Lancet 2006 367 : 168 176.
104. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003 114 : 294 298.
105. Bouillet L, Ponard D, Drouet C, Jullien D, Massot C. Angioedema and oral contraception. Dermatology 2003 206 : 106 109.
106. Pichler WJ, Lehner R, Spath PJ. Recurrent angioedema associated with hypogonadism or anti-androgen therapy. Ann Allergy 1989 63 : 301 305.
107. Visy B, Fust G, Varga L, Szendei G, Takacs E, Karadi I et al. Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol (Oxf) 2004 60 : 508 515.
108. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999 44 : 21 25.
109. Berkun Y, Shalit M. Hereditary angioedema first apparent in the ninth decade during treatment with ACE inhibitor. Ann Allergy Asthma Immunol 2001 87 : 138 139.
110. Bas M, Kojda G, Bier H, Hoffmann TK. Durch ACE-Hemmer induziertes Angioödem des Kopf-Hals-Bereichs. Eine Frage der Zeit HNO 2004 52 : 886 890.
111. Bas M, Hoffmann TK, Bier H, Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005 59 : 233 238.
112. Davis AE III. The pathophysiology of hereditary angioedema. Clin Immunol 2005 114 : 3 9.
113. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005 139 : 379 394.
114. Shiber JR. Angioedema of the arytenoids. N Engl J Med 2005 353 : e15.
115. Kojda G, Hafner D, Behne M, Wilhelm M. Pharmakologie Toxikologie Systematisch, 2nd edn. Bremen, London, Boston : UNI-MED AG, 2002.
116. Farkas H, Harmat G, Fust G, Varga L, Visy B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 2002 13 : 153 161.
117. Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002 68 : 307 309.
118. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999 57 : 1005 1032.
119. Bucca C. Take the side-effects of drugs into account. Lancet 2004 364 : 1285.
120. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002 25 : 73 76.
121. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976 295 : 1444 1448.
122. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999 353 : 1066 1067.
123. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004 164 : 910 913.
124. Bas M, Kojda G. Angioödem nach Einnahme von Irbesartan [Angioedema induced by irbesartan]. Apothekenmagazin 2005 23 : 254 255.
125. van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005 116 : 876 883.
126. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006 15 : 1077 1090.
127. Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006 117 : 476 477.
128. Icatibant. HOE 140, JE 049, JE049. Drugs R D 2005 6 : 239 244.
129. Proud D, Bathon JM, Togias AG, Naclerio RM. Inhibition of the response to nasal provocation with bradykinin by HOE-140: efficacy and duration of action. Can J Physiol Pharmacol 1995 73 : 820 826.
130. Rosenkranz B, Bork K, Frank J. Proof-of-concept study of icatibant (JE 049), a bradykinin B2 receptor antagonist in treatment of hereditary angioedema. Clin Pharmacol Ther 2005 77 : 2 (Abstract).
131. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B-2-receptor antagonist icatibant. Allergy 2006 61 : 1490 1492.